Measuring total ige is useful in detecting exacerbations in patients with allergic bronchopulmonary aspergillosis receiving omalizumab

The pathogenesis of allergic bronchopulmonary aspergillosis (ABPA), a hypersensitivity reaction to Aspergillus fumigatus antigens, is complex and not yet fully clarified. [...]the diagnosis might sometimes represent a challenge because there is no universal consensus on the diagnostic criteria originally proposed by Rosenberg et al.1 Nonetheless, IgE plays a key pathogenic role in the disease, and is currently accepted as a marker of both initial diagnosis and disease activity. [...]omalizumab, an mAb that binds to circulating IgE, has been repeatedly reported to successfully control ABPA within the initial months of treatment, both in retrospective case series3 and in a recent placebo-controlled registered clinical trial,4 but no long-term information is currently available.